SU2C hails FDA approval of alpelisib and fulvestrant new breast cancer treatment

(Stand Up To Cancer) SU2C welcomed the recent Food and Drug Administration (FDA) approval of alpelisib in combination with fulvestrant, the first and only new therapy for patients with a PIK3CA mutation in HR+/HER2- advanced metastatic breast cancer in both post-menopausal women and in men. Research by one of SU2C's inaugural Dream Teams, the SU2C PI3K Dream Team: 'Targeting The PI3K Pathway In Women's Cancers' contributed to the development of this treatment.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news